Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "CE"

7487 News Found

Aster implements India’s first IOeRT for cancer care
Healthcare | October 09, 2024

Aster implements India’s first IOeRT for cancer care

To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients


Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
News | October 09, 2024

Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals

Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic


AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
News | October 08, 2024

AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy

CSPC will receive an upfront payment of $100 million from AstraZeneca


Davaindia accelerates expansion with 1,165 operational stores
News | October 08, 2024

Davaindia accelerates expansion with 1,165 operational stores

Strategic focus on COCO-model with a nationwide reach of 501 stores


Calquence granted priority review in US for patients with untreated mantle cell lymphoma
Drug Approval | October 06, 2024

Calquence granted priority review in US for patients with untreated mantle cell lymphoma

Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy


AIIMS, New organises conference on ‘Advancing Oral Health in India’
Healthcare | October 06, 2024

AIIMS, New organises conference on ‘Advancing Oral Health in India’

Poor oral health (periodontal disease) impacts nearly 51% of Indians


Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
News | October 05, 2024

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025


Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility
News | October 04, 2024

Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility

US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years


Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
Drug Approval | October 04, 2024

Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin

This is used to treat central diabetes insipidus and bedwetting


Indoco Remedies receives final ANDA approval from the USFDA for Cetirizine Hydrochloride Tablets
Drug Approval | October 04, 2024

Indoco Remedies receives final ANDA approval from the USFDA for Cetirizine Hydrochloride Tablets

Cetirizine is used for relief of symptoms of hay fever and other allergic conditions